Incidence and Resolution of Eribulin-induced peripheral Neuropathy (IRENE)
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Breast cancer
- Focus Adverse reactions
- Acronyms IRENE
- Sponsors Eisai Co Ltd
- 18 Oct 2017 Planned End Date changed from 1 Sep 2021 to 1 Nov 2021.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 26 Sep 2016 New trial record